Regenhardt Robert W, Das Alvin S, Ohtomo Ryo, Lo Eng H, Ayata Cenk, Gurol Mahmut Edip
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
J Stroke Cerebrovasc Dis. 2019 Aug;28(8):2079-2097. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.006. Epub 2019 May 28.
Since the term "lacune" was adopted in the 1800s to describe infarctions from cerebral small vessels, their underlying pathophysiological basis remained obscure until the 1960s when Charles Miller Fisher performed several autopsy studies of stroke patients. He observed that the vessels displayed segmental arteriolar disorganization that was associated with vessel enlargement, hemorrhage, and fibrinoid deposition. He coined the term "lipohyalinosis" to describe the microvascular mechanism that engenders small subcortical infarcts in the absence of a compelling embolic source. Since Fisher's early descriptions of lipohyalinosis and lacunar stroke (LS), there have been many advancements in the understanding of this disease process. Herein, we review lipohyalinosis as it relates to modern concepts of cerebral small vessel disease (cSVD). We discuss clinical classifications of LS as well as radiographic definitions based on modern neuroimaging techniques. We provide a broad and comprehensive overview of LS pathophysiology both at the vessel and parenchymal levels. We also comment on the role of biomarkers, the possibility of systemic disease processes, and advancements in the genetics of cSVD. Lastly, we assess preclinical models that can aid in studying LS disease pathogenesis. Enhanced understanding of this highly prevalent disease will allow for the identification of novel therapeutic targets capable of mitigating disease sequelae.
自19世纪“腔隙”一词被用来描述脑小血管梗死以来,其潜在的病理生理基础一直不明,直到20世纪60年代查尔斯·米勒·费希尔对中风患者进行了多项尸检研究。他观察到血管呈现节段性小动脉紊乱,这与血管扩张、出血和纤维蛋白样沉积有关。他创造了“脂质透明变性”一词来描述在没有明显栓子来源的情况下导致皮质下小梗死的微血管机制。自费希尔早期对脂质透明变性和腔隙性卒中(LS)的描述以来,对这一疾病过程的认识有了许多进展。在此,我们回顾与脑小血管疾病(cSVD)现代概念相关的脂质透明变性。我们讨论LS的临床分类以及基于现代神经影像学技术的影像学定义。我们在血管和实质层面提供了LS病理生理学的广泛而全面的概述。我们还评论了生物标志物的作用、全身性疾病过程的可能性以及cSVD遗传学的进展。最后,我们评估有助于研究LS疾病发病机制的临床前模型。对这种高度流行疾病的深入了解将有助于识别能够减轻疾病后遗症的新治疗靶点。